Dr. Reddy's Laboratories Limited (RDY)
Similar size · 0.94x market cap
Drug Manufacturers - Specialty & Generic
YouTube · Q1 FY2027 · 2026-07-22
ELAN · NYSE
Drug Manufacturers - Specialty & Generic · United States
Snapshot 2026-09-28 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-11-06 (provider estimate, not issuer-confirmed).
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
Company websiteQ2 2026
Comparable businesses
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | ELANElanco Animal Health IncorporatedSnapshot 2026-09-28Financial period: 2026-06-30 | RDYDr. Reddy's Laboratories LimitedSnapshot 2026-09-28Financial period: 2026-06-30 | AMRXAmneal Pharmaceuticals, Inc.Snapshot 2026-09-28Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$11.17B | US$10.45B | US$6.93B | US$8.69Bn=2 |
| Forward P/EProvider forward earnings estimate | 17.41x | 19.36x | 16.70x | 18.03xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 14.75x | — | 13.14x | — |
| Revenue growthLatest quarter vs prior-year quarter | 10.2% | -5.6% | 9.9% | 2.1%n=2 |
| Operating marginLatest reported quarter | 8.6% | 4.3% | 18.3% | 11.3%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | 7.4% | — | -1.7% | — |
| Net debt / EBITDANet debt / trailing EBITDA | 3.68x | -0.17x | 3.86x | 1.84xn=2 |
| Debt / equityTotal debt / positive book equity | 0.64x | 0.19x | 23.87x | 12.03xn=2 |
| Trailing P/ETrailing twelve-month earnings | — | 30.59x | 41.48x | 36.03xn=2 |
| Price / bookPrice / positive book equity per share | 1.70x | 15.41x | 193.30x | 104.36xn=2 |
| EV / salesEnterprise value / trailing revenue | 2.96x | — | 2.90x | — |
| Earnings growthLatest quarter vs prior-year quarter | 440.5% | -68.7% | 157.1% | 44.2%n=2 |
| Gross marginTrailing twelve months | 55.4% | 50.2% | 39.8% | 45.0%n=2 |
| Net marginTrailing twelve months | -4.0% | 10.0% | 5.0% | 7.5%n=2 |
| Return on equityProvider trailing return; positive equity only | -3.0% | 8.8% | 613.0% | 310.9%n=2 |
| Free cash flow marginTrailing free cash flow / revenue | 16.5% | -1.2% | -3.7% | -2.4%n=2 |
| Dividend yieldIndicated annual dividend / price | — | 0.6% | — | — |
| Earnings payoutProvider trailing dividend payout | 0.0% | 20.2% | 0.0% | 10.1%n=2 |
| Current ratioCurrent assets / current liabilities | 2.05x | 1.90x | 2.21x | 2.05xn=2 |
| BetaProvider historical market sensitivity | 1.68 | 0.24 | 1.24 | 0.74n=2 |
Similar size · 0.94x market cap
Drug Manufacturers - Specialty & Generic
YouTube · Q1 FY2027 · 2026-07-22
Similar size · 0.62x market cap
Drug Manufacturers - Specialty & Generic
YouTube · Q2 2026 · 2026-07-30
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Price history loads separately.
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-28. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Presentation · 2026-08-07 · YouTube
Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.